Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
AFF4
REST API REST API
Homo sapiens
AFF4 is differentially expressed in 274 experiments: 143 organism parts: lung, testis, ... (141 more);, 175 disease states: normal, control, ... (173 more);, 79 cell types 373 cell lines 37 compound treatments and 79 other conditions.
Synonyms AF5Q31, MCEF
Orthologs AFF4 (Gallus gallus)   Aff4 (Mus musculus)   D3ZP74_RAT (Rattus norvegicus)   ENSCING00000005955 (Ciona intestinalis)   AFF4 (Bos taurus)   aff4 (Danio rerio)   lilli (Drosophila melanogaster)   aff4 (Xenopus laevis)   AFF4 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, regulation of transcription, DNA-dependent, transcription from RNA polymerase II promoter, nucleus, spermatid development, nucleolus, mitochondrion, sequence-specific DNA binding transcription factor activity
UniProt Accession Q9UHB7, C9JCE0
InterPro Term TF_AF4/FMR2
Search EB-eye ENSG00000072364
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-4717, ... (38 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
PC3
3
E-GEOD-5258, E-MEXP-2034, E-GEOD-14464
MCF7
2
E-GEOD-5258, E-MTAB-37
AGS
2
E-MTAB-37, E-GEOD-15460
KG1
2
E-MTAB-37, E-GEOD-24147
367 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, ... (38 experiments)

Factor Value U/D Experiments
centroblast
2
E-GEOD-15271, E-TABM-702
germ cell
1
E-MTAB-25
CD34 positive
1
1
E-GEOD-12662
CD34+
1
1
E-AFMX-5
neutrophil
1
E-GEOD-12662
wild_type
1
E-GEOD-20193
73 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-TABM-118, E-GEOD-16363, ... (54 experiments)

Factor Value U/D Experiments
benign prostatic hyperplasia
3
E-MEXP-2034, E-MEXP-1243, E-GEOD-7307
glioblastoma
3
E-MTAB-37, E-GEOD-4290, E-MTAB-62
control
1
3
E-GEOD-21912, E-GEOD-16363, E-GEOD-8121, E-GEOD-20602
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
colon carcinoma
2
E-MTAB-62, E-MTAB-37
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
169 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, E-TABM-782, E-GEOD-3720, ... (24 experiments)

Factor Value U/D Experiments
none
3
5
E-GEOD-20719, E-TABM-868, E-MEXP-1958, E-TABM-782, E-GEOD-5099, ... (8 experiments)
interferon-gamma + lipopolysaccharide
2
E-GEOD-5099, E-GEOD-7307
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
17beta-estradiol
4
1
E-GEOD-2292
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
Emdogain
1
E-MEXP-2645
31 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-GEOD-21374, ... (11 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-3891, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-GEOD-21138, E-GEOD-19665 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (8 experiments)

Genotype
studied in E-GEOD-22056, E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, E-MEXP-421, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-7011, E-MEXP-2657, E-GEOD-21612, E-GEOD-20504, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-GEOD-16363, E-GEOD-20876, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, ... (7 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Library source
studied in E-GEOD-19323

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-21750

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1509, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-22541, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Tumor size
studied in E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.366 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM